123 related articles for article (PubMed ID: 37462418)
21. Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis.
Mi M; Liu Z; Zheng X; Wen Q; Zhu F; Li J; Mungur ID; Zhang L
Leuk Res; 2021 Dec; 111():106693. PubMed ID: 34455197
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy.
Tyagi A; Abrari A; Khurana A; Tyagi S
J Cancer Res Ther; 2022; 18(4):1129-1136. PubMed ID: 36149172
[TBL] [Abstract][Full Text] [Related]
23. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL; van Eijk R; Böhringer S; van Wezel T; Raghoo R; Ruano D; Jansen PM; Briaire-de Bruijn I; de Groot FA; Kleiverda K; Te Boome L; Terpstra V; Levenga H; Nicolae A; Posthuma EFM; Focke-Snieders I; Hardi L; den Hartog WCE; Bohmer LH; Hogendoorn PCW; van den Berg A; Diepstra A; Nijland M; Lugtenburg PJ; Kersten MJ; Pals ST; Veelken H; Bovée JVMG; Cleven AHG; Vermaat JSP
Blood Adv; 2021 Oct; 5(19):3760-3775. PubMed ID: 34478526
[TBL] [Abstract][Full Text] [Related]
24. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
Oh S; Koo DH; Suh C; Kim S; Park BH; Kang J; Huh J
J Korean Med Sci; 2011 Dec; 26(12):1556-62. PubMed ID: 22147991
[TBL] [Abstract][Full Text] [Related]
26. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
Ichiki A; Carreras J; Miyaoka M; Kikuti YY; Jibiki T; Tazume K; Watanabe S; Sasao T; Obayashi Y; Onizuka M; Ohmachi K; Yoshiba F; Shirasugi Y; Ogawa Y; Kawada H; Nakamura N; Ando K
J Clin Exp Hematop; 2017; 57(2):54-63. PubMed ID: 29021515
[TBL] [Abstract][Full Text] [Related]
28. Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Asrini R; Ham MF; Asmarinah A; Harahap AS; Hardjolukito ESR
Mol Clin Oncol; 2022 Feb; 16(2):42. PubMed ID: 35003740
[TBL] [Abstract][Full Text] [Related]
29. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM
Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035
[TBL] [Abstract][Full Text] [Related]
30. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
31. Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue.
Reinders J; Altenbuchinger M; Limm K; Schwarzfischer P; Scheidt T; Strasser L; Richter J; Szczepanowski M; Huber CG; Klapper W; Spang R; Oefner PJ
Sci Rep; 2020 May; 10(1):7876. PubMed ID: 32398793
[TBL] [Abstract][Full Text] [Related]
32. An immunohistochemical study of diffuse large B-cell lymphoma with molecular subtyping based on Hans algorithm.
Ananthamurthy A; Murali M
Indian J Pathol Microbiol; 2023 Nov; ():. PubMed ID: 38394429
[TBL] [Abstract][Full Text] [Related]
33. The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.
Cardoso CC; Auat M; Santos-Pirath IM; Rudolf-Oliveira RCM; da Silva JP; Lange BG; Siegel D; de Moraes ACR; Del Moral JAG; Santos-Silva MC
Cytometry B Clin Cytom; 2018 May; 94(3):451-458. PubMed ID: 28509416
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome.
Gorodetskiy VR; Probatova NA; Vasilyev VI
Int J Rheum Dis; 2020 Apr; 23(4):540-548. PubMed ID: 32100426
[TBL] [Abstract][Full Text] [Related]
35. [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
Yin HF; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 39(2):158-62. PubMed ID: 17440591
[TBL] [Abstract][Full Text] [Related]
36. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
37. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
38. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.
Muppidi JR; Schmitz R; Green JA; Xiao W; Larsen AB; Braun SE; An J; Xu Y; Rosenwald A; Ott G; Gascoyne RD; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Vaidehi N; Staudt LM; Cyster JG
Nature; 2014 Dec; 516(7530):254-8. PubMed ID: 25274307
[TBL] [Abstract][Full Text] [Related]
39. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry.
Naz E; Mirza T; Danish F
Asian Pac J Cancer Prev; 2011; 12(12):3335-9. PubMed ID: 22471476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
